AtCor Medical Holdings Limited provided revenue guidance for the financial year 2017. The company anticipates revenue for the financial year to be between $4.3 and $5.0 million, compared with $5.0 million in financial year 2016. Non-pharma revenues in the US are expected to grow by 15-25% year on year (measured on a constant currency basis) despite the slower than anticipated uptake by clinicians. Sales to pharmaceutical companies are now forecast to be approximately AUD 1.0 million lower than the previous corresponding period. The reason for lower pharmaceutical revenues is the absence of major new hypertension drug trials for over three years. While there have been several minor trials in areas such as heart failure and diabetes, their commercial value has been less than anticipated.